InhaleRx (ASX: IRX) chief executive officer Darryl Davies joins Small Caps to discuss the company’s development plans for its novel inhaled cannabinoid formulation IRX211 in treating complex regional pain syndrome (CRPS).

Mr Davies said the trial will begin recruiting patients in May.

InhaleRx’s strategy is to develop novel cannabinoid-derived drug device combination medicines to treat areas of unmet need in pain management and mental health.

Articles:
https://smallcaps.com.au/inhalerx-ethics-approval-phase-1-trial-novel-drug-irx211-treating-crps/
https://smallcaps.com.au/inhalerx-makes-progress-inhaled-cannabinoid-drugs-crps-panic-disorder/
https://smallcaps.com.au/inhalerx-moves-forward-clinical-trials-drugs-address-mental-health-complex-pain/

For more information on InhaleRx:
https://smallcaps.com.au/stocks/IRX/

See omnystudio.com/listener for privacy information.